BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 28393224)

  • 21. Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma.
    Zou G; Ren B; Liu Y; Fu Y; Chen P; Li X; Luo S; He J; Gao G; Zeng Z; Xiong W; Li G; Huang Y; Xu K; Zhang W
    Cancer Sci; 2018 Nov; 109(11):3416-3427. PubMed ID: 30151927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The transcriptome of human mammary epithelial cells infected with the HCMV-DB strain displays oncogenic traits.
    Moussawi FA; Kumar A; Pasquereau S; Tripathy MK; Karam W; Diab-Assaf M; Herbein G
    Sci Rep; 2018 Aug; 8(1):12574. PubMed ID: 30135434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: a meta-analysis.
    Wang Z; Peng S; Jiang N; Wang A; Liu S; Xie H; Guo L; Cai Q; Niu Y
    Oncotarget; 2017 Nov; 8(60):102361-102370. PubMed ID: 29254251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
    Mrklić I; Spagnoli GC; Juretić A; Pogorelić Z; Tomić S
    Acta Histochem; 2014 Jun; 116(5):740-6. PubMed ID: 24560456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    Thike AA; Tan PH; Ikeda M; Iqbal J
    Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
    Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
    Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer.
    Dimas-González J; Maldonado-Lagunas V; Díaz-Chávez J; López-Arellano ME; Muñoz-Camacho J; Terán-Porcayo MA; Lagunas-Martínez A
    Oncol Rep; 2017 May; 37(5):3026-3036. PubMed ID: 28393224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
    Chen W; Qiu J; Shen YM
    Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
    Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.
    Ali Y; Abd Hamid S
    Tumour Biol; 2016 Jan; 37(1):47-55. PubMed ID: 26482620
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.